Treatment of Metastatic Breast Carcinoma Refractory to Doxorubicin With Liposomal-Annamycin.
Annual rept. 23 Sep 97-22 Sep 98
M D ANDERSON CANCER CENTER HOUSTON TX
Pagination or Media Count:
Nine patients with metastatic breast carcinoma refractory to doxorubicin were entered in a Phase II study of liposomal-annamycin, a new anthracycline antibiotic which has shown ability to circumvent multidrug resistance. A total of 14 doses of liposomal- annamycin were given at three different dose levels. Toxicity was mild and limited to granulocytopenia in less than 50 of patients. No antitumor responses were seen.
- Medicine and Medical Research